中国医学创新2024，Vol.21Issue(31)：159-162,4.DOI:10.3969/j.issn.1674-4985.2024.31.037
血清肿瘤标志物CYFRA21-1、NSE与CA125对肺癌的临床诊断价值探析
The Clinical Diagnostic Value of Serum Tumor Markers CYFRA21-1,NSE and CA125 in Lung Cancer
摘要
Abstract
Objective:To analyze the clinical diagnostic value of serum tumor markers cytokeratin 19 fragment(CYFRA21-1),neuron-specific enolase(NSE)and carbohydrate cancer antigen 125(CA125)in lung cancer.Method:A total of 106 patients with lung cancer and 100 patients with benign pulmonary diseases treated in Clinical Laboratory of Shangrao Dongxin Fifth Hospital from January 2020 to December 2022 were selected for study.The levels of serum CYFRA21-1,NSE and CA125 were detected,and their diagnostic efficacy in lung cancer were analyzed.Result:The levels of CYFRA21-1,NSE and CA125 in lung cancer group were higher than those in benign lung group,with statistical significance(P<0.05).The ROC curve was drawn with CYFRA21-1,NSE and CA125 as test variables,1=lung cancer group and 0=benign lung group as effect variables,AUC for CYFRA21-1 was 0.650,with a 95%CI of 0.566 to 0.734;AUC for NSE was 0.643,with a 95%CI of 0.567 to 0.718;AUC for CA125 was 0.612,with a 95%CI of 0.535 to 0.690;the sensitiveness of combined diagnosis was 83.02%,the specificity was 94.00%,and the accuracy was 88.35%.Compared with the gold standard,the results were consistent(Kappa=0.768).Conclusion:In the diagnosis of lung cancer,the combined application of tumor markers CYFRA21-1,NSE and CA125 can accurately diagnose early lung cancer and has clinical application value.关键词
肿瘤标志物/细胞角蛋白19片段/神经元特异性烯醇化酶/糖类癌抗原125/肺癌Key words
Tumor markers/CYFRA21-1/NSE/CA125/Lung cancer引用本文复制引用
李露..血清肿瘤标志物CYFRA21-1、NSE与CA125对肺癌的临床诊断价值探析[J].中国医学创新,2024,21(31):159-162,4.基金项目
上饶市科技计划项目(2022CZDX31) （2022CZDX31）
